KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a N/A change, with the full-year FY2025 number at $3.2 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $3.2 million for Q4 2025 at Xenon Pharmaceuticals, up from $3.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.2 million in Q4 2025 to a low of $3.2 million in Q3 2025.